Risperdal Tapering Guide
risperidone
Boxed Warning
Increased mortality in elderly patients with dementia-related psychosis.
Overview
Risperidone is an atypical antipsychotic approved for schizophrenia, bipolar mania, and irritability associated with autistic disorder. It has high affinity for dopamine D2 and serotonin 5-HT2A receptors and carries a notable risk of hyperprolactinemia.
0.5mg, 1mg, 2mg, 3mg, 4mg
Tablets: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg; Orally disintegrating tablets (M-Tab): 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg; Oral solution: 1mg/mL; Long-acting injection (Risperdal Consta): 12.5mg, 25mg, 37.5mg, 50mg
Category C (risk cannot be ruled out)
Mechanism of Action
Potent antagonist at dopamine D2 and serotonin 5-HT2A receptors. Also antagonizes alpha-1, alpha-2 adrenergic, and histamine H1 receptors. Higher D2 affinity than most atypicals contributes to EPS risk at higher doses and hyperprolactinemia.
Taper Notes
Liquid formulation (1mg/mL) available for precise dosing. Withdrawal can include supersensitivity psychosis.
Hyperbolic Tapering Guidance
Oral solution provides precise dosing. Extremely gradual taper essential, especially for long-term use. Risk of dopamine supersensitivity.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- CYP2D6 inhibitors (fluoxetine, paroxetine) increase risperidone levels
- CYP3A4 inducers (carbamazepine, phenytoin, rifampin) decrease risperidone levels
- CYP3A4 inhibitors (ketoconazole, itraconazole) increase risperidone levels
Food Interactions
- Food does not significantly affect absorption
- Avoid alcohol (additive CNS depression)
Contraindications
- Known hypersensitivity to risperidone or paliperidone
Toxicity
Hyperprolactinemia (highest among atypicals). Extrapyramidal symptoms at higher doses. Metabolic effects (weight gain, hyperglycemia, dyslipidemia). Orthostatic hypotension. Tardive dyskinesia. NMS rarely.
Pharmacokinetics
ADME Profile
Well absorbed after oral administration. Bioavailability ~70% (oral solution) to ~66% (tablets). Tmax ~1 hour. Food does not significantly affect absorption.
~1–2 L/kg
Hepatic via CYP2D6 (primary) to the active metabolite 9-hydroxyrisperidone (paliperidone), which has similar pharmacological activity. CYP3A4 is a minor pathway.
Renal (~70%) and fecal (~14%). In extensive CYP2D6 metabolizers, active moiety (risperidone + 9-OH-risperidone) half-life is ~20 hours.
~90% (risperidone), ~77% (9-hydroxyrisperidone)
~5–8 mL/min/kg (total active moiety clearance)
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Risperdal (risperidone) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D 2021 — A method for tapering antipsychotic treatment that may minimize the risk of relapse (Schizophrenia Bulletin)
- Tranter R, Healy D 1998 — Antipsychotic withdrawal symptoms: phenomenology and pathophysiology (Journal of Psychopharmacology)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Royal College of Psychiatrists — Antipsychotics — UK clinical guidance on antipsychotic prescribing and discontinuation
- Council for Evidence-Based Psychiatry (CEP UK) — Evidence-based critique of long-term antipsychotic prescribing
- Deprescribing.org — Antipsychotic deprescribing algorithm for insomnia and BPSD
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — antipsychotic tapering forum — Community archive of antipsychotic taper experiences
- Mad in America — antipsychotic archive — Independent journalism on antipsychotics and withdrawal
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- RxISK — adverse drug reaction reporting — Independent database of antipsychotic adverse-effect reports
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.